Chemotherapy for lung cancer: The state of the art in 2009

Expert Review of Anticancer Therapy

Volumn 9, Issue 10, 2009, Pages 1365-1378

  Higgins, Michaela J ^a   Ettinger, David S ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Lung cancer; Non small cell; Small cell; Systemic therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; IFOSFAMIDE; LAPATINIB; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; UFT; UNINDEXED DRUG; VANDETANIB; VINBLASTINE; VINCRISTINE; VINDESINE;

ADJUVANT THERAPY; ADVANCED CANCER; ARTERY THROMBOSIS; ASTHENIA; BLEEDING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; LOW DRUG DOSE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG HEMORRHAGE; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SMALL CELL CANCER; LUNG SURGERY; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECURRENT CANCER; REVIEW; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CHEMOTHERAPY, ADJUVANT; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 70350599566     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.115     Document Type: Review

References (98)

1. Mountain CF. Revisions in the international system for staging lung cancer. Chest 111(6), 1710-1717 (1997).
2. Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-Small-Cell Lung Cancer Collaborative Group. BMJ 311(7010), 899-909 (1995). • Meta-analysis of 52 randomized clinical trials that demonstrated a nonsignificant survival advantage to adjuvant cisplatin-based chemotherapy over surgery alone.
3. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 350(4), 351-360 (2004). •• First meta-analysis to demonstrate significantly improved survival associated with adjuvant cisplatin-based chemotherapy over surgery alone. (Pubitemid 38101630)
4. Douillard JY, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 7(9), 719-727 (2006). (Pubitemid 44283661)
5. Strauss GM, Herndon JE 2nd, Maddaus MA et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J. Clin. Oncol. 26(31), 5043-5051 (2008).
6. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N. Engl. J. Med. 352(25), 2589-2597 (2005). (Pubitemid 41007845)
7. Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26(21), 3552-3559 (2008).
8. Le Chevalier T, Dunant A, Arriagada R et al. Long-term results of the International Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small-cell lung cancer (NSCLC). ASCO Annual Meeting Chicago, IL, USA 30 May-3 June 2008 (Abstract 7507).
9. Hamada C, Tanaka F, Ohta M et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J. Clin. Oncol. 23(22), 4999-5006 (2005). (Pubitemid 46224006)
10. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355(10), 983-991 (2006). • Patients with excision repair cross-complementation group 1 (ERCC1)-negative tumors by immunohistochemistry benefitted from cisplatin-based adjuvant chemotherapy while patients with ERCC1-positive tumors did not. (Pubitemid 44343542)
11. Depierre A, Milleron B, Moro-Sibilot D et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II and IIIa non-small-cell lung cancer. J. Clin. Oncol. 20(1), 247-253 (2002). (Pubitemid 34032618)
12. Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann. Thorac. Surg. 53(6), 992-998 (1992).
13. Rosell R, Gomez-Codina J, Camps C et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N. Engl. J. Med. 330(3), 153-158 (1994). (Pubitemid 24026882)
14. Roth JA, Fossella F, Komaki R et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J. Natl Cancer Inst. 86(9), 673-680 (1994). (Pubitemid 24983600)
15. van Meerbeeck JP, Kramer GW, van Schil PE et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J. Natl Cancer Inst. 99(6), 442-450 (2007).
16. Albain KS, Rusch VW, Crowley JJ et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group Phase II study 8805. J. Clin. Oncol. 13(8), 1880-1892 (1995).
17. Choi NC, Carey RW, Daly W et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J. Clin. Oncol. 15(2), 712-722 (1997). (Pubitemid 27074241)
18. Eberhardt W, Wilke H, Stamatis G et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a Phase II trial. J. Clin. Oncol. 16(2), 622-634 (1998). (Pubitemid 28135609)
19. Thomas M, Rube C, Semik M et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J. Clin. Oncol. 17(4), 1185 (1999). (Pubitemid 29162942)
20. Thomas M, Rube C, Hoffknecht P et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 9(7), 636-648 (2008).
21. Albain KS, Swann S, Rusch VR et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer. Lancet 374(9687), 379-386 (2009). •• Neoadjuvant chemoradiation provided a survival advantage over chemotherapy alone only in patients who underwent lobectomy.
22. Fournel P, Robinet G, Thomas P et al. Randomized Phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J. Clin. Oncol. 23(25), 5910-5917 (2005). (Pubitemid 46300207)
23. Hanna N, Neubauer M, Yiannoutsos C et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J. Clin. Oncol. 26(35), 5755-5760 (2008).
24. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346(2), 92-98 (2002). (Pubitemid 34438899)
25. Rosell R, Gatzemeier U, Betticher DC et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann. Oncol. 13(10), 1539-1549 (2002). (Pubitemid 36040773)
26. Ardizzoni A, Boni L, Tiseo M et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J. Natl Cancer Inst. 99(11), 847-857 (2007).
27. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18(10), 2095-2103 (2000). (Pubitemid 30324363)
28. Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22(9), 1589-1597 (2004). (Pubitemid 41079796)
29. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005). (Pubitemid 41058344)
30. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26(21), 3543-3551 (2008).
31. Scagliotti G, Hanna N, Fossella F et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14(3), 253-263 (2009).
32. Herbst RS, Sun Y, Korfee S et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind Phase III trial (ZODIAC). J. Clin. Oncol. 27(15S), (2009) (Abstract CRA8003).
33. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22(11), 2184-2191 (2004). (Pubitemid 41095154)
34. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542-2550 (2006). •• The addition of bevacizumab to carboplatin and paclitaxel chemotherapy in advanced or recurrent non-small-cell lung cancer significantly improved response rates and median survival but was associated with increased risk of bleeding and pulmonary hemorrhage. (Pubitemid 46940175)
35. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J. Clin. Oncol. 27(8), 1227-1234 (2009).
36. Fidias PM, Dakhil SR, Lyss AP et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 27(4), 591-598 (2009).
37. Belani CP, Brodowicz T, Ciuleanu T et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized Phase III study in advanced non-small-cell lung cancer (NSCLC). J. Clin. Oncol. 27(15S), (2009) (Abstract CRA8000).
38. Cappuzzo F, Coudert B, Wierzbicki R et al. Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the Phase III SATURN study. 13th World Conference on Lung Cancer. International Association for the Study of Lung Cancer. San Francisco, CA, USA 31 July-4 August 2009 (Abstract A2.1).
39. Miller VA, O'Connor P, Soh C, Kabbinavar F. ATLAS Investigators. A randomized, double-blind, placebo-controlled, Phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small-cell lung cancer (NSCLC). J. Clin. Oncol. 27(15S), (2009) (Abstract LBA8002).
40. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J. Clin. Oncol. 21(12), 2237-2246 (2003). (Pubitemid 46621858)
41. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: a randomized trial. JAMA 290(16), 2149-2158 (2003).
42. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496), 1527-1537 (2005). (Pubitemid 41540110)
43. Maruyama R, Nishiwaki Y, Tamura T et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J. Clin. Oncol. 26(26), 4244-4252 (2008).
44. Lee D, Kim S, Park K et al. A randomized open-label study of gefitinib versus docetaxel in patients with advanced/metastatic non-small-cell lung cancer (NSCLC) who have previously received platinum-based chemotherapy. ASCO Annual Meeting Chicago, IL, USA 30 May-3 June 2008 (Abstract 8025).
45. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised Phase III trial. Lancet 373(9674), 1525-1531 (2009). • The addition of the monoclonal antibody cetuximab to cisplatin and vinorelbine chemotherapy was associated with 1-month overall survival advantage in both adenocarcinomas and squamous carcinomas.
46. Butts CA, Bodkin D, Middleman EL et al. Randomized Phase II study of gemcitabine plus cisplatin or carboplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J. Clin. Oncol. 25(36), 5777-5784 (2007).
47. Borghaei H, Langer CJ, Millenson M et al. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small-cell lung cancer (NSCLC): results of OPN-017. J. Thorac. Oncol. 3(11), 1286-1292 (2008).
48. Janne PA, Gurubhagavatula S, Yeap BY et al. Outcomes of patients with advanced non-small-cell lung cancer treated with gefitinib (ZD1839, 'Iressa') on an expanded access study. Lung Cancer 44(2), 221-230 (2004). (Pubitemid 38482055)
49. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004). (Pubitemid 38637993)
50. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J. Clin. Oncol. 25(5), 587-595 (2007).
51. Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl Cancer Inst. 97(9), 643-655 (2005). (Pubitemid 40812628)
52. Galleges Ruiz MI, Floor K, Steinberg SM et al. Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. Br. J. Cancer 100(1), 145-152 (2009).
53. Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH. EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J. Intern. Med. 24(1), 48-54 (2009).
54. Asahina H, Yamazaki K, Kinoshita I et al. A Phase II trial of gefitinib as first-line therapy for advanced non-small-cell lung cancer with epidermal growth factor receptor mutations. Br. J. Cancer 95(8), 998-1004 (2006). (Pubitemid 44606825)
55. Inoue A, Suzuki T, Fukuhara T et al. Prospective Phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J. Clin. Oncol. 24(21), 3340-3346 (2006). (Pubitemid 46638887)
56. Sequist LV, Martins RG, Spigel D et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol. 26(15), 2442-2449 (2008).
57. Yoshida K, Yatabe Y, Park JY et al. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small-cell lung cancer. J. Thorac. Oncol. 2(1), 22-28 (2007). (Pubitemid 47163924)
58. Paz-Ares L, Sanchez JM, Garcia-Velasco A et al. A prospective Phase II trial of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). ASCO Annual Meeting Atlanta, GA, USA 2-6 June 2006 (Abstract 7020).
59. Mok T, Wu Yi-L, Thongprasert S et al. Phase III randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced NSCLC (I-PASS). Ann. Oncol. 19(Suppl. 8), (2008) (Abstract LBA2).
60. Tam IY, Chung LP, Suen WS et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small-cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin. Cancer Res. 12(5), 1647-1653 (2006).
61. De Roock W, Piessevaux H, De Schutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 19(3), 508-515 (2008). (Pubitemid 351325672)
62. Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26(3), 374-379 (2008). (Pubitemid 351171687)
63. O'Byrne KJ, Bondarenko I, Barrios C et al. Molecular and clinical predictors of outcome for cetuximab in non-small-cell lung cancer (NSCLC): data from the FLEX study. J. Clin. Oncol. 27(15S) (2009) (Abstract 8007).
64. Langer CJ. The 'lazarus response' in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation. J. Clin. Oncol. 27(9), 1350-1354 (2009).
65. Inoue A, Kobayashi K, Usui K et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J. Clin. Oncol. 27(9), 1394-1400 (2009).
66. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23(11), 2544-2555 (2005).
67. Herbst RS, O'Neill VJ, Fehrenbacher L et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J. Clin. Oncol. 25(30), 4743-4750 (2007). (Pubitemid 350086476)
68. Carter CA, Chen C, Brink C et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small-cell lung carcinoma. Cancer Chemother. Pharmacol. 59(2), 183-195 (2007). (Pubitemid 44885148)
69. Socinski MA, Novello S, Brahmer JR et al. Multicenter Phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J. Clin. Oncol. 26(4), 650-656 (2008). (Pubitemid 351264362)
70. Fukuoka M, Furuse K, Saijo N et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J. Natl Cancer Inst. 83(12), 855-861 (1991).
71. Sundstrom S, Bremnes RM, Kaasa S et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized Phase III trial with 5 years' follow-up. J. Clin. Oncol. 20(24), 4665-4672 (2002). (Pubitemid 36025283)
72. Takada M, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J. Clin. Oncol. 20(14), 3054-3060 (2002). (Pubitemid 34791094)
73. Turrisi AT 3rd, Kim K, Blum R et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N. Engl. J. Med. 340(4), 265-271 (1999).
74. Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N. Engl. J. Med. 341(7), 476-484 (1999).
75. Bischof M, Debus J, Herfarth K et al. Surgery and chemotherapy for small cell lung cancer in stages I-II with or without radiotherapy. Strahlenther. Onkol. 183(12), 679-684 (2007). (Pubitemid 350175411)
76. Brock MV, Hooker CM, Syphard JE et al. Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: its time has come. J. Thorac. Cardiovasc. Surg. 129(1), 64-72 (2005).
77. Roth BJ, Johnson DH, Einhorn LH et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a Phase III trial of the Southeastern Cancer Study Group. J. Clin. Oncol. 10(2), 282-291 (1992).
78. Skarlos DV, Samantas E, Kosmidis P et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann. Oncol. 5(7), 601-607 (1994).
79. Byrne A, Carney DN. Small cell lung cancer in the elderly. Semin. Oncol. 21(3 Suppl. 6), 43-48 (1994). (Pubitemid 24267700)
80. Evans WK, Radwi A, Tomiak E et al. Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer. Am. J. Clin. Oncol. 18(2), 149-155 (1995).
81. Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346(2), 85-91 (2002). (Pubitemid 34438898)
82. Hanna N, Bunn PA Jr, Langer C et al. Randomized Phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J. Clin. Oncol. 24(13), 2038-2043 (2006). (Pubitemid 46622112)
83. Lara PN Jr, Natale R, Crowley J et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J. Clin. Oncol. 27(15), 2530-2535 (2009).
84. Socinski MA, Smit EF, Lorigan P et al. Phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC): interim results. ASCO Annual Meeting Chicago, IL, USA 30 May-3 June 2008 (Abstract NSA).
85. Heigener DF, Freitag L, Eschbach C et al. Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED- SCLC): final results of a randomised Phase III trial. ASCO Annual Meeting Chicago, IL, USA 30 May-3 June 2008 (Abstract 7513).
86. Chen G, Huynh M, Fehrenbacher L et al. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J. Clin. Oncol. 27(9), 1401-1404 (2009).
87. Ohyanagi F, Horiike A, Okano Y et al. Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer. Cancer Chemother. Pharmacol. 61(3), 503-508 (2008). (Pubitemid 350275986)
88. Shah C, Ready N, Perry M et al. A multicenter Phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung Cancer 57(1), 84-88 (2007). (Pubitemid 46843346)
89. Sawa T, Yana T, Takada M et al. Multicenter Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial. Invest. New Drugs 24(2), 151-158 (2006). (Pubitemid 43723907)
90. Takeda K, Takifuji N, Negoro S et al. Phase II study of amrubicin, 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study. Invest. New Drugs 25(4), 377-383 (2007). (Pubitemid 46944847)
91. Yana T, Negoro S, Takada M et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest. New Drugs 25(3), 253-258 (2007). (Pubitemid 46774694)
92. Onoda S, Masuda N, Seto T et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J. Clin. Oncol. 24(34), 5448-5453 (2006). (Pubitemid 46623179)
93. Jotte RM, Conkling PR, Reynolds C et al. Results of a randomized Phase II trial of amrubicin vs topotecan in patients with extensive-disease small cell lung cancer sensitive to first-line platinum-based chemotherapy. 13th World Conference on Lung Cancer. International Association for the Study of Lung Cancer. San Francisco, CA, USA 31 July-4 August 2009.
94. Ettinger DS, Jotte RM, Lorigan P et al. Amrubicin monotherapy in patients with extensive disease small cell lung cancer refractory to first-line platinum-based chemotherapy. 13th World Conference on Lung Cancer. International Association for the Study of Lung Cancer. San Francisco, CA, USA 31 July-4 August 2009.
95. Potti A, Mukherjee S, Petersen R et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N. Engl. J. Med. 355(6), 570-580 (2006). (Pubitemid 44200650)
96. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24(23), 3726-3734 (2006). (Pubitemid 46622311)
97. Souglakos J, Boukovinas I, Taron M et al. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br. J. Cancer 98(10), 1710-1715 (2008). (Pubitemid 351684679)
98. National Comprehensive Cancer Network. Practice Guidelines in Oncology - v.2.2009 Non-small-cell Lung Cancer http://misc.medscape.com/images/586/420/ nscl.pdf